AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD).
The deal, valued at up to $1.2 billion, includes an upfront payment and development milestones for the bretisilocin program. As part of the transaction, Gilgamesh will spin off a new entity, Gilgamesh Pharma Inc., to manage its employees and other programs, such as blixeprodil (GM-1020) and a collaboration with AbbVie.
